

A3

7. (Amended) The cilostazol preparation according to claim 30, wherein said surfactant is an alkyl sulfate salt.

8. (Amended) The cilostazol preparation according to claim 29, wherein said fine powder of cilostazol is a fine powder having average particle diameter of about 7 μm or less.

A4

12. (Amended) The cilostazol preparation according to claim 31, wherein said fine powder of cilostazol is a fine powder having average particle diameter of about 5 μm or less.

A5

20. (Amended) A sustained release preparation of cilostazol which comprises any one of the cilostazol preparations of claims 1, 4, 7-10, 12-14, and 29-31 coated with a sustained release coating material.

21. (Amended) The sustained release preparation according to claim 20, which has a capability of dissolving cilostazol even at the lower portion of the digestive tract.

A6

29. (New) The cilostazol preparation according to claim 4, wherein said surfactant is one or more selected from the group essentially consisting of polyglycerin fatty acid ester, polyoxyethylene sorbitan fatty acid ester, polyethylene glycol fatty acid ester, polyoxyethylene alkyl ether, polyoxyethylene castor oil, sucrose ester of fatty acid and alkyl sulfate salt.

30. (New) The cilostazol preparation according to claim 29, wherein said surfactant is one or more selected from the group essentially consisting of polyoxyethylene sorbitan fatty acid ester, polyoxyethylene alkyl ether and alkyl sulfate salt.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com